Since the report of third quarter results, Cingulate, Inc. (NASDAQ:CING) has executed a $5 million capital raise, completed its fast-fed study and reported safety results from its Phase III trials.
Cingulate (NASDAQ:CING – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback